Navigation Links
Honeywell Expands Aclar(R) Production for Pharmaceutical Industry
Date:3/26/2008

Upgrade to boost capacity by up to 23 percent for moisture-barrier film

PHILADELPHIA, March 26 /PRNewswire/ -- Honeywell (NYSE: HON) announced today that it will expand production of Aclar(R) film to meet growing demand for the clear, moisture-barrier material, which is used extensively in pharmaceutical packaging.

An upgrade of existing production capability, combined with overall productivity improvements, is expected to boost Aclar production by up to 23 percent by end of 2008 at the business' Pottsville, Pa. facility.

"This is another step in our continued strategy to invest to meet the packaging needs of the pharmaceutical industry now and in the future," said Jeff Czarnecki, global segment leader for the specialty films segment of Honeywell Performance Products. Czarnecki noted that the business implemented productivity improvements at the Pottsville site in 2007 which also boosted capacity.

Rick Knight, global business manager for healthcare, said pharmaceutical companies worldwide continue to demand thermoformed packaging material with superior barrier capabilities. "Honeywell is committed to supporting pharmaceutical companies globally as they introduce new products to the marketplace," Knight said.

The announcement was made at INTERPHEX(TM), the world's largest and most comprehensive pharmaceutical conference and exhibition. The event focuses on leading-edge technology, education, and sourcing of products and services that drive scientific innovation for life sciences manufacturing.

As part of its commitment to the pharmaceutical industry, Honeywell is continuing its technical training and educational series to address critical aspects of thermoform packaging. The program consists of half- and one-day workshops.

Aclar is a polychlorotrifluoroethylene (PCTFE) fluoropolymer film that has excellent moisture barrier and chemical stability. Aclar film is crystal clear, biochemically inert, chemical-resistant, nonflammable, and plasticizer- and stabilizer-free.

In addition to Aclar, Honeywell Specialty Films manufactures Capran(R) biaxially oriented nylon film, also known as biaxially oriented polyamide (BOPA) film; Capran(R) heat stabilized nylon film; Aclon(TM) fluoropolymer resins, which provide the highest moisture barrier of any clear thermoplastic resins; and Honeywell PCTFE, ECTFE and PMP barrier films for high performance industrial applications.

Honeywell Specialty Materials, based in Morristown, N.J., is a $4.9 billion, global leader in providing customers with high-performance specialty materials, including fluorine products; specialty films and additives; advanced fibers and composites; intermediates; specialty chemicals; electronic materials and chemicals; and technologies and materials for petroleum refining.

Honeywell International is a $36 billion diversified technology and manufacturing leader, serving customers worldwide with aerospace products and services; control technologies for buildings, homes and industry; automotive products; turbochargers; and specialty materials. Based in Morris Township, N.J., Honeywell's shares are traded on the New York, London and Chicago Stock Exchanges. For additional information, please visit http://www.honeywell.com.

This report contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of fact, that address activities, events or developments that we or our management intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Forward-looking statements are based on management's assumptions and assessments in light of past experience and trends, current conditions, expected future developments and other relevant factors. They are not guarantees of future performance, and actual results, developments and business decisions may differ from those envisaged by our forward-looking statements. Our forward-looking statements are also subject to risks and uncertainties, which can affect our performance in both the near- and long-term. We identify the principal risks and uncertainties that affect our performance in our Form 10-K and other filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Honeywell
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Murad Expands International Presence With Appointment of Danny Guez
2. Sigma-Aldrich Amends Credit Facility and Expands Commercial Paper Program
3. VIE Healthcare Expands Its Operations in the Midwest, and Obtains First Local Client
4. Eating Disorders Program at Lucile Packard Childrens Hospital Expands to Include Young Adults
5. Dollar Thrifty Automotive Group Expands Mobile Managed Services Contract with InfoLogix
6. Life Spine Expands Home Office Space, More Than Doubling Space Occupied
7. Millennium Expands IBD Franchise with Addition of New Development Candidate
8. inVentiv Clinical Expands Operations to Emerging Latin American Region
9. Anti-Aging/Genetic Health Leader Suracell, Inc. Expands Internationally
10. AlphaDetail, Inc. Expands Management Team
11. ANSYS Expands HPC Benchmarking Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 , ... ... distinction of Customer Excellence upon National Registry of Emergency Medical Technicians ... drives Financial Performance,” said Dr. Jan G. West, Ph.D. , CEO & ...
(Date:4/26/2017)... ... , ... Miami native and local periodontist Dr. John Paul Gallardo ... back in 1991 that this journey would have taken me into so many learning ... Dr. Gallardo has pioneered implant dentistry innovation, evolving into an internationally recognized leader in ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more about ... ) that demonstrates how this advanced plant breeding technology is a more efficient ... fewer resources. It highlights the business’ principles, research and collaboration efforts in this ...
(Date:4/26/2017)... (PRWEB) , ... April 26, ... ... which provides an agile ecosystem and domain expertise for sponsors and CROs ... randomization and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... topical cream that’s the first in a new class of photodynamic cosmetics (PDC). ... appearance of skin, visibly reduce outward signs of aging, and minimize the appearance ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 ... Surgical drainage devices are tubes used to remove excess ... include, blood, serum, pus, urine, bile or lymph. Surgical ... types of surgery such as orthopedics surgery, cardiovascular surgery, ... device is prophylactic post-surgery to prevent accumulation of fluid ...
Breaking Medicine Technology: